Faculty

Faculty

Christopher Flowers

MD, MS

The University of Texas MD Anderson Cancer Center, Houston, Texas

Division Head, Division of Cancer Medicine, Chair, Professor, Department of Lymphoma/Myeloma, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine

Faculty

Matthew Lunning

DO

University of Nebraska Medical Center, Omaha, Nebraska

Professor, Medical Director, Gene and Cellular Therapy, Assistant Vice Chancellor for Clinical Research, Fred and Pamela Buffett Cancer Center

Faculty

Sonali M Smith

MD

The University of Chicago, Chicago, Illinois

Elwood V Jensen Professor of Medicine, Chief, Section of Hematology/Oncology, Co-Leader, Cancer Service Line

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Additional faculty to be announced.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Rational Incorporation of CD79b- Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

• Key factors in the selection of initial therapy for patients with DLBCL
• Extended follow-up from the Phase III POLARIX trial comparing polatuzumab vedotin with rituximab/cyclophosphamide/doxorubicin/prednisone (R-CHP) to R-CHOP for patients with previously untreated DLBCL; clinical activity observed with polatuzumab vedotin/R-CHP in various patient subsets
• Appropriate selection of patients to receive polatuzumab vedotin as a component of up-front therapy for DLBCL
• Efficacy and safety findings from the Phase III POLARGO study of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin for patients with R/R DLBCL; potential role of this regimen
• Available and emerging results, including those from the Phase III SUNMO trial, with polatuzumab vedotin combined with bispecific antibodies for patients with R/R DLBCL

MODULE 2: Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and FL

• Extended follow-up from the Phase II L-MIND study supporting the use of tafasitamab/lenalidomide for patients with R/R DLBCL
• Optimal sequencing of tafasitamab/lenalidomide for individual patients with R/R DLBCL
• Biological rationale for the evaluation of tafasitamab for FL
• Key efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide and rituximab (R2) for R/R FL or marginal zone lymphoma
• FDA approval of tafasitamab/R2 for patients with R/R FL; selection of appropriate candidates for this approach

MODULE 3: Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL

• Extended follow-up from the Phase II LOTIS-2 study supporting the use of loncastuximab tesirine for patients with R/R DLBCL
• Optimal sequencing of loncastuximab tesirine for individual patients with R/R DLBCL and ongoing studies designed to further define its role
• Initial results from the Phase Ib LOTIS-7 study of loncastuximab tesirine in combination with glofitamab for R/R DLBCL; implications for clinical practice and ongoing research
• Available data with loncastuximab tesirine for other subtypes of non-Hodgkin lymphoma (NHL)
• Recent NCCN Guidelines inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 4: Current and Future Role of Bruton Tyrosine Kinase (BTK) Inhibition in Therapy for NHL

• Key efficacy and safety outcomes with the addition of acalabrutinib to bendamustine/rituximab (BR) and maintenance rituximab for patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for transplant
• Recent FDA approval of acalabrutinib/BR as a front-line regimen for MCL; identification of optimal candidates for this strategy
• Published research findings with and ongoing studies of covalent BTK inhibitors as a component of up-front chemotherapy-free combination regimens for MCL
• Published efficacy and safety data from the Phase II ROSEWOOD study of zanubrutinib in combination with obinutuzumab for patients with FL who had received 2 or more previous systemic therapies
• FDA approval of zanubrutinib/obinutuzumab for R/R FL; current clinical role and ongoing Phase III evaluation
• Published clinical trial experience with BTK inhibitors for patients with newly diagnosed DLBCL
• Design, eligibility criteria and primary and secondary endpoints of the Phase III ESCALADE trial of acalabrutinib in combination with R-CHOP for patients aged 65 or younger with untreated non-GCB DLBCL; estimated completion date

MODULE 5: Potential Role of Bcl-2 Inhibitors in Therapy for MCL

• Available data with and current clinical role of venetoclax as monotherapy or in combination with rituximab or a BTK inhibitor for patients with R/R MCL
• Mechanistic similarities and differences between venetoclax and the next-generation Bcl-2 inhibitor sonrotoclax; implications for efficacy and tolerability
• Emerging positive findings from the BGB-11417-201 trial evaluating sonrotoclax monotherapy for R/R MCL
• FDA breakthrough therapy designation for sonrotoclax for R/R MCL and potential clinical role
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CELESTIAL-RRMCL study comparing sonrotoclax and zanubrutinib to placebo and zanubrutinib for patients with R/R MCL; estimated completion date

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom the use of CD79b-targeted therapy would be appropriate.
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and apply this information in patient education discussions.
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted antibody-drug conjugates for patients with relapsed/refractory (R/R) DLBCL and FL.
• Evaluate available clinical trial findings with Bruton tyrosine kinase inhibitors for patients with mantle cell lymphoma (MCL), FL and DLBCL, and determine the role of these agents in current and future clinical management.
• Assess emerging research findings with Bcl-2 inhibitors for patients with R/R MCL in order to prepare for the potential clinical availability of this novel treatment strategy.
• Recall new data with agents and strategies currently under investigation for various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Incyte Corporation.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

Faculty

Faculty

Farrukh T Awan

MD

University of Texas Southwestern Medical Center, Dallas, Texas

Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program, Harold C Simmons Comprehensive Cancer Center

Faculty

Robin Klebig

MSN, APRN, CNP, AOCNP

Mayo Clinic, Rochester, Minnesota

Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology

Faculty

Mollie Moran

APRN-CNP, AOCNP

The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio

Nurse Practitioner

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting

MODULE 1: Current Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma (NHL)

• Design of bispecific antibodies to engage 2 disease targets with 1 molecule; potential therapeutic advantages over traditional monoclonal antibodies
• Scientific rationale for the selection of CD20 and CD3 as targets for bispecific antibodies in NHL; mechanism of antitumor activity
• Pharmacological similarities and differences among the various approved (eg, glofitamab, epcoritamab, mosunetuzumab) and investigational (eg, odronextamab) CD20 x CD3 bispecific antibodies for NHL; implications for efficacy, tolerability and ease of use
• Similarities and differences between bispecific antibodies and chimeric antigen receptor T-cell therapy
• FDA-approved indications for mosunetuzumab, glofitamab and epcoritamab; optimal selection and sequencing of bispecific antibodies for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

MODULE 2: Tolerability Concerns with Bispecific Antibodies for NHL

• Pathophysiology of the CRS and neurotoxicity observed with bispecific antibody therapy, including immune effector cell-associated neurotoxicity syndrome (ICANS)
• Comparative incidence and severity of CRS with bispecific antibodies available for various NHL subtypes
• Common signs and symptoms and typical course of CRS
• Clinical presentation of neurotoxicity/ICANS and common symptoms, such as delirium, dysphasia, lethargy, difficulty concentrating and confusion
• Guideline-endorsed approaches for monitoring, mitigation and management of CRS and neurotoxicity; role of corticosteroids, tocilizumab and other supportive care interventions
• Spectrum, frequency and severity of other common tolerability concerns, such as cytopenia, infections, fatigue, rash, musculoskeletal pain and gastrointestinal (GI) adverse events (AEs), with bispecific antibodies for patients with NHL

MODULE 3: Role of Polatuzumab Vedotin in Therapy for DLBCL

• Structural components of polatuzumab vedotin and mechanism of antitumor activity
• Extended follow-up with polatuzumab vedotin/R-CHP (rituximab, cyclophosphamide, doxorubicin and prednisone) for previously untreated DLBCL
• Current role of polatuzumab vedotin as a component of up-front therapy for DLBCL; appropriate selection of candidates for this strategy
• Efficacy and safety findings with polatuzumab vedotin in combination with chemoimmunotherapy (bendamustine/rituximab, rituximab/gemcitabine/oxaliplatin) or bispecific antibodies (mosunetuzumab) for patients with relapsed/refractory (R/R) DLBCL; current and potential role of these regimens

MODULE 4: Tolerability Considerations with Polatuzumab Vedotin

• Rates and severity of peripheral neuropathy with polatuzumab vedotin; appropriate use of dose adjustments and other management strategies
• Incidence of cytopenias and infections with polatuzumab vedotin-containing regimens; appropriate monitoring of complete blood counts (CBCs) during therapy
• Spectrum and incidence of GI AEs with polatuzumab vedotin-based therapy; strategies for management
• Differences, if any, in the tolerability of polatuzumab vedotin in the up-front versus the R/R setting; implications for AE monitoring and management

MODULE 5: Optimal Application of Loncastuximab Tesirine for Patients with DLBCL or FL

• Mechanism of action and structural makeup of the anti-CD19 antibody-drug conjugate loncastuximab tesirine
• Long-term findings with loncastuximab tesirine for R/R DLBCL; patient selection and optimal sequencing
• Available data with loncastuximab tesirine in combination with other therapies and for other NHL subtypes
• Recent NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 6: Tolerability Considerations with Loncastuximab Tesirine

• Incidence, severity and management of edema and effusions with loncastuximab tesirine
• Rates of myelosuppression and infections with loncastuximab tesirine; appropriate monitoring of CBCs during therapy
• Spectrum of cutaneous reactions documented with loncastuximab tesirine, such as photosensitivity reactions, rash and erythema; recommended strategies for mitigation and management
• Initial dosing and dose-modification strategies with loncastuximab tesirine; recommended premedications, such as dexamethasone and G-CSF, for some or all patients

MODULE 7: Current and Future Role of Covalent and Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitors in the Management of Chronic Lymphocytic Leukemia (CLL)

• Indications for initiating active therapy for patients with previously untreated CLL
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve and R/R CLL; application in current up-front decision-making
• Comparative antitumor activity of BTK inhibitors alone and in combination with anti-CD20 antibodies in the up-front setting; implications for therapy selection

MODULE 8: Tolerability of Covalent and Noncovalent BTK Inhibitors

• Incidence and severity of cardiac arrhythmias, including atrial fibrillation or flutter, documented with approved covalent BTK inhibitors
• Probability of other cardiovascular toxicities, such as stroke, hypertension and bruising or bleeding events, with covalent BTK inhibitor therapy
• Spectrum and frequency of clinically relevant noncardiovascular toxicities, including cytopenias, infections, headache, dermatologic symptoms, arthralgia/myalgia and GI events, with covalent BTK inhibitors
• Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving covalent BTK inhibitors
• Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
• Incidence and severity of cardiac arrhythmias and other cardiovascular and noncardiovascular toxicities documented with pirtobrutinib
• Appropriate monitoring for and management of treatment-related AEs in patients receiving pirtobrutinib
• Safety profile of pirtobrutinib in the front-line setting

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
• Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted antibody-drug conjugate (ADC) therapy would be appropriate.
• Appraise available research findings with and the current clinical role of CD19-targeted ADCs for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review data with and the current and potential role of this strategy for patients with newly diagnosed and R/R CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/NHLandCLL/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Klebig and Ms Moran have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.

MODERATOR — Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Lilly.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.